EGFR and breast cancer: Treatment of BC, particularly in HER2-positive subtypes, has been revolutionized by targeted therapies like lapatinib, a dual tyrosine kinase inhibitor (TKI) that blocks HER2 and EGFR signaling (Yang et al., 2020).